Early research (Phase 1)Study completedNCT00757809What this trial is testingStudy Evaluating The Tolerability Of Multiple Doses Of HKI-272Who this might be right forHealthy Subjects Puma Biotechnology, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT01008150What this trial is testingPhase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast CancerWho this might be right forBreast Cancer NSABP Foundation Inc 141
Not applicableNo Longer AvailableNCT01956253What this trial is testingSingle Subject Neratinib in Bladder Cancer (NRR)Who this might be right forBladder Cancer UNC Lineberger Comprehensive Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT01953926What this trial is testingBasket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsWho this might be right forSolid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations Puma Biotechnology, Inc. 582
Early research (Phase 1)Temporarily pausedNCT05372614What this trial is testingTesting the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneWho this might be right forMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)Study completedNCT01827267What this trial is testingNeratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerWho this might be right forHER2-mutant Non-Small Cell Lung Cancer Puma Biotechnology, Inc. 62
Large-scale testing (Phase 3)Looking for participantsNCT05760612What this trial is testingAdjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabWho this might be right forEarly-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Early research (Phase 1)Study completedNCT02334501What this trial is testingOpen-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy SubjectsWho this might be right forHealthy Puma Biotechnology, Inc. 15
Testing effectiveness (Phase 2)WithdrawnNCT01960023What this trial is testingSafety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal CancerWho this might be right forColorectal Cancer NSABP Foundation Inc
Early research (Phase 1)Ended earlyNCT02593708What this trial is testingPhase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+Who this might be right forSolid Tumor Michelle Melisko 6
Testing effectiveness (Phase 2)Looking for participantsNCT05919108What this trial is testingNeoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast CancersWho this might be right forAnatomic Stage I Breast CancerAnatomic Stage II Breast CancerAnatomic Stage III Breast Cancer+1 more Vanderbilt-Ingram Cancer Center 30
Early research (Phase 1)Active Not RecruitingNCT04502602What this trial is testingNiraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerWho this might be right forAdvanced Solid TumorOvarian Cancer Virginia Commonwealth University 18
Not applicableStudy completedNCT05599334What this trial is testingA Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With NeratinibWho this might be right forBreast CancerAdjuvant TherapyHER2-positive Breast Cancer Pierre Fabre Medicament 111
Testing effectiveness (Phase 2)Study completedNCT01111825What this trial is testingTemsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerWho this might be right forBreast Cancer Puma Biotechnology, Inc. 99
Testing effectiveness (Phase 2)Study completedNCT00706030What this trial is testingStudy Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast CancerWho this might be right forBreast CancerAdvanced Malignant Solid Tumors Puma Biotechnology, Inc. 92
Not applicableLooking for participantsNCT06693024What this trial is testingAdjuvant Therapy With Neratinib in HER2 Positive Early Breast CancerWho this might be right forHER2-positive Breast Cancer Shu Wang 2,806
Testing effectiveness (Phase 2)Active Not RecruitingNCT05252988What this trial is testingThree Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibWho this might be right forEarly-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive Spanish Breast Cancer Research Group 177
Testing effectiveness (Phase 2)Study completedNCT01670877What this trial is testingNeratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerWho this might be right forBreast Neoplasms Washington University School of Medicine 56
Testing effectiveness (Phase 2)UnknownNCT03812393What this trial is testingEvaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastWho this might be right forTriple Negative Breast CancerEarly-stage Breast CancerHER2-positive Breast Cancer West Cancer Center 27
Early research (Phase 1)Active Not RecruitingNCT03065387What this trial is testingNeratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationWho this might be right forAdvanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more M.D. Anderson Cancer Center 93